Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

TCR Sequencing Reveals the Distinct Development of Fetal and Adult Human Vγ9Vδ2 T Cells.

Papadopoulou M, Tieppo P, McGovern N, Gosselin F, Chan JKY, Goetgeluk G, Dauby N, Cogan A, Donner C, Ginhoux F, Vandekerckhove B, Vermijlen D.

J Immunol. 2019 Aug 14. pii: ji1900592. doi: 10.4049/jimmunol.1900592. [Epub ahead of print]

PMID:
31413106
2.

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Depreter B, Weening KE, Vandepoele K, Essand M, De Moerloose B, Themeli M, Cloos J, Hanekamp D, Moors I, D' Hont I, Denys B, Uyttebroeck A, Van Damme A, Dedeken L, Snauwaert S, Goetgeluk G, De Munter S, Kerre T, Vandekerckhove B, Lammens T, Philippé J.

Haematologica. 2019 Aug 1. pii: haematol.2019.222612. doi: 10.3324/haematol.2019.222612. [Epub ahead of print]

3.

Nanobody Based Dual Specific CARs.

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, Kerre T, Abken H, Vandekerckhove B.

Int J Mol Sci. 2018 Jan 30;19(2). pii: E403. doi: 10.3390/ijms19020403.

4.

The checkpoint for agonist selection precedes conventional selection in human thymus.

Verstichel G, Vermijlen D, Martens L, Goetgeluk G, Brouwer M, Thiault N, Van Caeneghem Y, De Munter S, Weening K, Bonte S, Leclercq G, Taghon T, Kerre T, Saeys Y, Van Dorpe J, Cheroutre H, Vandekerckhove B.

Sci Immunol. 2017 Feb 24;2(8). pii: eaah4232. doi: 10.1126/sciimmunol.aah4232.

5.

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.

Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, Debets R, Vermijlen D, Abken H, Vandekerckhove B.

Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017.

6.

In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.

Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, De Mulder K, Heirman C, Stauss H, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Thielemans K, Kerre T, Vandekerckhove B.

Leukemia. 2014 Apr;28(4):830-41. doi: 10.1038/leu.2013.285. Epub 2013 Oct 4.

PMID:
24091848
7.

RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Snauwaert S, Vanhee S, Goetgeluk G, Verstichel G, Van Caeneghem Y, Velghe I, Philippé J, Berneman ZN, Plum J, Taghon T, Leclercq G, Thielemans K, Kerre T, Vandekerckhove B.

Haematologica. 2012 Oct;97(10):1539-47. doi: 10.3324/haematol.2012.065581. Epub 2012 Apr 24.

Supplemental Content

Loading ...
Support Center